Tang Han, Tian Hui, Yue Weiming, Li Lin, Li Shuhai, Gao Cun, Si Libo, Qi Lei, Lu Ming, Hu Wensi
Department of Thoracic Surgery, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China.
Oncol Rep. 2014 May;31(5):2454-60. doi: 10.3892/or.2014.3116. Epub 2014 Mar 27.
Lysosome-associated protein transmembrane-4β (LAPTM4B) is a novel cancer-related gene that is upregulated in many tumors, and which plays important roles in carcinogenesis. It has two alleles, LAPTM4B 1 and LAPTM4B 2. LAPTM4B 1 contains only one copy of a 19-bp sequence in the first exon, whereas LAPTM4B 2 contains two tight tandem segments. Previous studies have shown that LAPTM4B 2 is a risk factor for susceptibility and prognosis of many tumors. The present study investigated the relationship between LAPTM4B polymorphism and non-small cell lung cancer (NSCLC) susceptibility and prognosis. We identified LAPTM4B genotypes with polymerase chain reaction (PCR) in peripheral blood samples. In the adjusted multivariate logistic regression analysis, we found that LAPTM4B 1/2, LAPTM4B 2/2 exhibited 1.48-fold [95% confidence interval (CI), 1.076-2.037] and 2.855-fold (95%CI, 1.722-4.734) increases in the risk of developing NSCLC compared with non-LAPTM4B 2 carriers. Furthermore, our results showed that overall survival time and disease-free survival time of patients with LAPTM4B 2 were significantly shorter than in patients carrying LAPTM4B 1 (P=0.001 and P=0.001, respectively). In addition, multivariate Cox regression analysis revealed that LAPTM4B 2 was also an independent prognostic factor for NSCLC. These results suggest that LAPTM4B polymorphisms may be a prospective marker for evaluating the risk and prognosis of NSCLC.
溶酶体相关蛋白跨膜4β（LAPTM4B）是一种新型的癌症相关基因，在许多肿瘤中上调，并在致癌过程中发挥重要作用。它有两个等位基因，LAPTM4B 1和LAPTM4B 2。LAPTM4B 1在第一个外显子中仅包含一个19碱基序列拷贝，而LAPTM4B 2包含两个紧密串联片段。先前的研究表明，LAPTM4B 2是许多肿瘤易感性和预后的危险因素。本研究调查了LAPTM4B基因多态性与非小细胞肺癌（NSCLC）易感性和预后的关系。我们通过聚合酶链反应（PCR）在外周血样本中鉴定LAPTM4B基因型。在调整后的多因素逻辑回归分析中，我们发现与非LAPTM4B 2携带者相比，LAPTM4B 1/2、LAPTM4B 2/2发生NSCLC的风险分别增加了1.48倍[95%置信区间（CI），1.076 - 2.037]和2.855倍（95%CI，1.722 - 4.734）。此外，我们的结果显示，LAPTM4B 2患者的总生存时间和无病生存时间明显短于携带LAPTM4B 1的患者（分别为P = 0.001和P = 0.001）。此外，多因素Cox回归分析显示，LAPTM4B 2也是NSCLC的独立预后因素。这些结果表明，LAPTM4B基因多态性可能是评估NSCLC风险和预后的一个前瞻性标志物。
